[Updated on Apr. 18] Integration of CiNii Articles into CiNii Research

Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society

  • Arima Hiroshi
    Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
  • Iwama Shintaro
    Department of Endocrinology and Diabetes, Nagoya University Hospital, Nagoya 466-8560, Japan
  • Inaba Hidefumi
    The First Department of Medicine, Wakayama Medical University, Wakayama 641-8509, Japan
  • Ariyasu Hiroyuki
    The First Department of Medicine, Wakayama Medical University, Wakayama 641-8509, Japan
  • Makita Noriko
    Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan
  • Otsuki Michio
    Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
  • Kageyama Kazunori
    Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki 036-8562, Japan
  • Imagawa Akihisa
    Department of Internal Medicine (I), Osaka Medical College, Takatsuki 569-8686, Japan
  • Akamizu Takashi
    The First Department of Medicine, Wakayama Medical University, Wakayama 641-8509, Japan

Search this article

Abstract

<p>Immune checkpoint inhibitors (ICIs) have become a promising treatment for advanced malignancies. However, these drugs can induce immune-related adverse events (irAEs) in several organs, including skin, gastrointestinal tract, liver, muscle, nerve, and endocrine organs. Endocrine irAEs comprise hypopituitarism, primary adrenal insufficiency, thyroid dysfunction, hypoparathyroidism, and type 1 diabetes mellitus. These conditions have the potential to lead to life-threatening consequences, such as adrenal crisis, thyroid storm, severe hypocalcemia, and diabetic ketoacidosis. It is therefore important that both endocrinologists and oncologists understand the clinical features of each endocrine irAE to manage them appropriately. This opinion paper provides the guidelines of the Japan Endocrine Society and in part the Japan Diabetes Society for the management of endocrine irAEs induced by ICIs.</p>

Journal

  • Endocrine Journal

    Endocrine Journal 66 (7), 581-586, 2019

    The Japan Endocrine Society

Citations (11)*help

See more

References(26)*help

See more

Related Articles

See more

Related Data

See more

Related Books

See more

Related Dissertations

See more

Related Projects

See more

Related Products

See more

Details

Report a problem

Back to top